article thumbnail

Exercise training outcomes in patients with chronic heart failure with reduced ejection fraction depend on patient background

Frontiers in Cardiovascular Medicine

Background The aim of this study was to identify significant factors affecting the effectiveness of exercise training using information of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) study.

Exercise 111
article thumbnail

Cardiopulmonary exercise testing in Fabry disease: is it an early marker of cardiomyopathy?

Heart BMJ

Cardiomyopathy is a primary determinant of prognosis in FD and typically presents as a heart failure (HF) with a preserved ejection fraction phenotype. Cardiomyopathy is a primary determinant of prognosis in FD and typically presents as a heart failure (HF) with a preserved ejection fraction phenotype.

article thumbnail

One Of The Biggest Impact Things You Can Do To Live Longer.

Dr. Paddy Barrett

Death from heart disease: 51% reduction in risk. Heart Failure: 69% reduction in risk. To benefit from exercise, you do not need to run marathons; you probably just need to walk around your local park. Why Does Exercise Make Such A Difference? Should You Only Focus On Exercise? Let me be clear.

Exercise 119
article thumbnail

Diabetes Med for Kidney Stones? Exercise and Heart Failure

Med Page Today

(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.

article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

DAIC

FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As

article thumbnail

Potassium Nitrate in Heart Failure With Preserved Ejection Fraction

JAMA Cardiology

This study assesses the impact of chronic inorganic nitrate administration on exercise tolerance in a larger trial of participants with heart failure with preserved ejection fraction.